ArcticZymes enters RNA therapeutics market with two new enzymes targeting manufacturing and analytical efficiency
Tromsø, Norway - 27 October 2026 - ArcticZymes Technologies ASA (OSE: AZT) today announced the early-access launch of RiboCleanT dsDNase and RiboCleaveT 1, its first enzymes developed specifically for RNA therapeutics manufacturing and analysis. The launch coincides with the opening of the 33rd ESGCT Annual Congress at the Congress Centre Hamburg, Germany (27-30 October 2026).
As RNA therapeutics advance toward commercial-scale manufacturing, improving process efficiency, reducing costs and simplifying analytical workflows are becoming increasingly important. ArcticZymes' two new enzymes address these challenges at critical stages of RNA manufacturing and quality analysis.
RiboCleanT dsDNase can be integrated directly into existing IVT workflows without additional buffer or calcium and is modelled to reduce nuclease costs per batch by more than 80%. RiboCleanT dsDNase delivered comparable DNA-removal performance to reference DNase I while using 10 x fewer units, corresponding to a 40-fold reduction in DNase protein mass added to the IVT workflow. Despite using 10 times fewer enzyme units than DNase I, RiboCleanT dsDNase showed no detectable difference in RNA integrity or yield under the tested conditions.
RiboCleaveT 1 simplifies sample preparation steps for mRNA cap-efficiency analysis by replacing a multistep RNase H-based workflow with a single sequence -specific digestion. Without requiring guide oligonucleotides, the enzyme reduces sample preparation time from approximately six hours to 30 minutes, while remaining compatible with existing analytical readout methods. This streamlined approach is modelled to reduce total assay costs by more than 80%.
"RNA has proven it works. The challenge our customers now face is making it faster, simpler and more cost-effective to develop and manufacture," said Michael B. Akoh, CEO of ArcticZymes Technologies. "The launch of RiboClean dsDNase and RiboCleave 1 demonstrates how we are delivering on our strategy to diversify our product portfolio and expand into new markets, while applying our proven enzyme expertise to deliver measurable improvements for our customers."
Both products are available to order now through ArcticZymes' open early-access program. Visit ArcticZymes at ESGCT booth number D-06, go to https://arcticzymes.com/advanced-therapies/rna-manufacturing, or contact support@arcticzymes.com to find out more.
For more information, please contact:
ArcticZymes Technologies ASA CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15 CFO, Børge Sørvoll Tel +47 952 90187 ir@arcticzymes.com
About ArcticZymes Technologies
ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, in vitro diagnostics (IVD) and biomanufacturing. The company has pioneered salt-active nucleases and continues to develop enzyme solutions that support efficient and reliable production of advanced therapeutics. www.arcticzymes.com